Skip to main content

Table 1 Demographic and basic clinical parameters at treatment start

From: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Baseline parameter

Females

Males

Overall

N (%)

24 (53.3)

21 (46.7)

45

Age, mean (SD), years

38.6 (14.2)

30.2 (9.5)

34.7 (12.8)

Age at ERT start, mean (SD), years

38.7 (14.1)

30.2 (9.5)

34.7 (12.8)

Age at ERT start, median (range), years

37.2 (15.6–61.4)

31.4 (14.9–44.9)

34.5 (14.9–61.4)

BMI, mean (SD), kg/m2

23.5 (3.6)

21.6 (3.5)

22.6 (3.6)

Systolic BP, mean (SD), mmHg

127.3 (13.2)

126.2 (16.0)

126.8 (14.4)

Diastolic BP, mean (SD), mmHg

72.3 (9.1)

68.2 (10.3)

70.4 (9.8)

Heart rate, mean (SD), bpm

64.0 (13.1)

65.1 (7.7)

64.5 (10.8)

Diabetes, n (%)

0 (0)

0 (0)

0 (0)

Current smoker, n (%)

2 (8.3)

3 (14.3)

5 (11.1)

Arterial hypertension, n (%)

2 (8.3)

3 (14.3)

5 (11.1)

  1. BMI: body mass index; bpm: beats per minute; BP: blood pressure; ERT: enzyme replacement therapy; SD: standard deviation